The only FDA approved therapeutic use of Endothelium-Derived Relaxing Factor is
**Core Concept**
The **Endothelium-Derived Relaxing Factor (EDRF)**, also known as **Nitric Oxide (NO)**, plays a crucial role in vascular relaxation. It is a key molecule involved in the regulation of blood pressure and flow. The therapeutic use of EDRF or NO is primarily focused on its vasodilatory effects.
**Why the Correct Answer is Right**
The correct answer is related to the use of **Nitric Oxide (NO)** in the treatment of **persistent pulmonary hypertension of the newborn (PPHN)**. NO is a potent vasodilator of pulmonary vessels, and its inhalation can help reduce pulmonary vascular resistance without causing systemic hypotension. This selective effect makes it an ideal therapeutic agent for PPHN.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it is not the primary FDA-approved use.
**Option B:** Incorrect as it does not relate to the known therapeutic application of EDRF or NO.
**Option C:** Incorrect because, although NO has various effects, this is not its only FDA-approved therapeutic use.
**Option D:** This option is not provided, but any other use would not be the sole FDA-approved indication.
**Clinical Pearl / High-Yield Fact**
Inhalation of **Nitric Oxide (NO)** is a lifesaving therapy for **persistent pulmonary hypertension of the newborn (PPHN)**, highlighting the importance of understanding the therapeutic applications of EDRF or NO. This knowledge can be critical in neonatal care.
**Correct Answer:** D. Inhalation for persistent pulmonary hypertension of the newborn.